PET imaging for cancer immunotherapy: the Immuno-PET

Affiliations

¹ Melanoma Institute Australia, The University of Sydney, Sydney, Australia; Faculty of Medicine and Health, The University of Sydney, Sydney, Australia; Royal North Shore and Mater Hospitals, Sydney, Australia. Electronic address: alexander.menzies@sydney.edu.au.
² IRCCS National Cancer Institute, Fondazione Senatore G. Pascale, Napoli, Italy.

Free article

Editorial

A M Menzies et al. Ann Oncol. 2022 Jan.

Free article

. 2022 Jan;33(1):13-14.

doi: 10.1016/j.annonc.2021.11.003. Epub 2021 Nov 19.

¹ Melanoma Institute Australia, The University of Sydney, Sydney, Australia; Faculty of Medicine and Health, The University of Sydney, Sydney, Australia; Royal North Shore and Mater Hospitals, Sydney, Australia. Electronic address: alexander.menzies@sydney.edu.au.
² IRCCS National Cancer Institute, Fondazione Senatore G. Pascale, Napoli, Italy.

No abstract available

Conflict of interest statement

Disclosure AMM has served on advisory boards for BMS, MSD, Novartis, Roche, Pierre-Fabre, QBiotics. SL has declared no conflicts of interest.

⁸⁹Zr-pembrolizumab imaging as a non-invasive approach to assess clinical response to PD-1 blockade in cancer.
Kok IC, Hooiveld JS, van de Donk PP, Giesen D, van der Veen EL, Lub-de Hooge MN, Brouwers AH, Hiltermann TJN, van der Wekken AJ, Hijmering-Kappelle LBM, Timens W, Elias SG, Hospers GAP, Groen HJM, Uyterlinde W, van der Hiel B, Haanen JB, de Groot DJA, Jalving M, de Vries EGE. Kok IC, et al. Ann Oncol. 2022 Jan;33(1):80-88. doi: 10.1016/j.annonc.2021.10.213. Epub 2021 Nov 1. Ann Oncol. 2022. PMID: 34736925